Trademarkia Logo

Canada

C$
Squiggle Design
DEFAULT - SEARCHED

Last Applicant/ Owned by

Evelo Biosciences, Inc.

620 Memorial Drive, Suite 200WCambridge, MA 02139

US

Serial Number

2005588 filed on 9th Jan 2020

Correspondent Address

KATHARINE ZAYACK

(Zayack & Associates Inc.)38 Gifford StreetToronto

ONTARIO

CA

M5A3J1

Squiggle Design

Trademark usage description

pharmaceuticals used to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; pharma Read More

Vienna Information


20 . 5 . 7

Plans, schematic drawings, diagrams, curves, outlinesPlans, schémas, diagrammes, courbes, tracés

26 . 11 . 1

One line or one bandUne ligne ou une bande

26 . 11 . 13

Wavy lines or bands, zigzag lines or bandsLignes ou bandes ondulées, en dents de scie

26 . 1 . 1

CirclesCercles

26 . 1 . 3

One circle or ellipseUn cercle ou une ellipse

26 . 1 . 24

Circles or ellipses with dark surfaces or parts of surfacesCercles ou ellipses avec surface ou partie de la surface foncée

26 . 13 . 1

Stains, spots, blots, brush strokesTaches, coups de pinceau

24 . 17 . 1

Punctuation marksSignes de ponctuation

24 . 17 . 2

DotsPoints

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 8

Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.Lettres liées à un élément figuratif ou contenant un élément figuratif -- Note: Les lettres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet sont classées dans la division 27.3.

Classification Information


Class [005]
Pharmaceuticals used to prevent disease in the nature of cancer, cancer symptoms, cancer-related diseases and side effects of cancer therapies; Pharmaceuticals used to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases; pharmaceuticals used to prevent disease in the nature of allergies and disrupted microbial community associated with allergies; Pharmaceuticals used to prevent disease in the nature of metabolic disorders; pharmaceuticals used to prevent cardiovascular, neuro-degenerative, and neuro-psychiatric diseases; pharmaceuticals used to treat and cure neoplastic conditions, pre-neoplastic conditions and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure inflammation, neuro-inflammation, and autoimmune diseases and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure allergies and disrupted microbial community associated with allergies in human and animal subjects; pharmaceuticals used to treat and cure metabolic disorders and disrupted microbial community associated with aforementioned conditions in human and animal subjects; pharmaceuticals used to treat and cure cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with aforementioned conditions in human and animal subjects ;pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of neoplastic conditions, pre-neoplastic conditions and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of inflammation, neuro-inflammation, and autoimmune diseases and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of allergies and disrupted microbial community associated with allergies; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of metabolic disorders and disrupted microbial community associated with the aforementioned conditions; pharmaceuticals used to maintain and restore health to human or animal subjects via treatment of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases and disrupted microbial community associated with the aforementioned conditions; live bacteria, inactivated bacteria, recombinant bacteria and bacterial extracts; biological preparations in the nature of microorganisms to prevent disease in the nature of neoplastic conditions and pre-neoplastic conditions in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of inflammation, neuro-inflammation, and autoimmune diseases in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of allergies in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of metabolic disorders in animal or human subjects; biological preparations in the nature of microorganisms to prevent disease in the nature of cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of microorganisms to treat and cure neoplastic conditions and pre-neoplastic conditions in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure inflammation and autoimmune diseases in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure allergies in animal or human subjects; biological preparations in the nature of microorganisms to treat and cure metabolic disorders and cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases in animal or human subjects; biological preparations in the nature of microorganisms to maintain and restore health in animal or human subjects via treatment of inflammation, neuro-inflammation, autoimmune diseases, allergies, metabolic disorders, cardiovascular, neuro-degenerative, neuro-inflammatory and neuro-psychiatric diseases; biological preparations in the nature of microorganisms to maintain and restore health in animal or human subjects via treatment of neoplastic conditions and pre-neoplastic conditions; cultures of microorganisms and preparation of microorganisms in the nature of bacterial and bacteriological preparations, all for medical and veterinary purposes, the foregoing for medical purposes; vaccines; therapeutic vaccines; vaccine preparations.


Classification kind code

11

Class [042]
Medical research; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines.


Classification kind code

11

Mark Details


Serial Number

2005588

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 14
on 23rd Dec 2024
Default Notice Sent
Submitted for opposition 22
on 5th Jun 2024
Search Recorded
Submitted for opposition 20
on 5th Jun 2024
Examiner's First Report
Submitted for opposition 287
on 14th Apr 2022
Pre-Assessment Letter Sent
Submitted for opposition 31
on 22nd Jan 2020
Formalized
Submitted for opposition 1
on 10th Jan 2020
Created
Submitted for opposition 30
on 9th Jan 2020
Filed